This has been taken advantage of when testing potential treatments, where the systemic administration of a selected liposome-formulated cGMP analog with PKG inhibitory properties was shown to protect RP retinas from retinal degeneration and to preserve the photoreceptor function [9]. This evidence concerns the gene PRKG1 and retinal degeneration.